As of September 30, reported cash and cash equivalents of $2.3M and current liabilities of $14.4M, which includes an $8.6M warrant liability. The company believes that it has sufficient resources available to fund business operations through January 2025. “Q3 2024 was marked with significant progress. We were very pleased with the SEISMiC B study results in early cardiogenic shock showing significant improvement in many measures of cardiac function and blood pressure along with a favorable safety profile in patients with heart failure and cardiogenic shock..” said CEO Craig Fraser. “With trial execution and active operations comes the need for capital and we successfully completed transactions providing resources for our near-term needs as well as secured an equity line of credit to potentially support future requirements. Looking forward, we plan to accelerate enrollments in the istaroxime SCAI Stage C cardiogenic shock study with a planned interim data read out in early Q2 2025 as well as providing guidance on our strategy and planned activities with our oncology preclinical aPKCi inhibitor assets. Given what we believe to be strong data and market need, the Company is turning attention to business development activities to secure additional licenses and partnerships for our multi-asset cardiovascular platform with the objective to secure non-dilutive capital and partner resources to advance the assets to potential commercialization.”
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on WINT:
- Windtree Therapeutics Appoints Jed Latkin as New CEO
- Windtree Therapeutics announces CEO Fraser to retire, Latkin to succeed
- Windtree Therapeutics Inc (WINT) Q3 Earnings Cheat Sheet
- Windtree Therapeutics issued Hong Kong patent for istaroxime
- Windtree Therapeutics initiates SEISMiC C study of istaroxime
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
